Receive The Newest Study Notifications

Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome

by Lance Smith | Jan 6, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Company Continues to Expect Top-line Data in First Half of 2020 REDWOOD CITY, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (NASDAQ: SLNO, the Company or Soleno), a clinical-stage biopharmaceutical company developing novel therapeutics for...

First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension

by Lance Smith | Jan 6, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3 LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) — ChromaDex Corp. (NASDAQ:CDXC), the global...

New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study

by Lance Smith | Jan 6, 2020 | Study Scavenger Clinical Trial Recruitment Platform

SALT LAKE CITY, Jan. 06, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item...

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis

by Lance Smith | Jan 6, 2020 | Study Scavenger Clinical Trial Recruitment Platform

NEWARK, Calif., Jan. 6, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated. Hereditary hemochromatosis is a...

BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

by Lance Smith | Jan 6, 2020 | Study Scavenger Clinical Trial Recruitment Platform

The PROOF trial, a Phase 3 trial of infigratinib in first-line cholangiocarcinoma, is currently enrolling SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary QED Therapeutics announced today that it has secured both...

Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

by Lance Smith | Jan 6, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Next-Generation Cardiac Myosin Inhibitor Advances In Clinical Trial Designed to Assess Effects Using Two-Week Dose Titration Schedule SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that...